ACELRX PHARMACEUTICALS
HAYWARD, California, United States · Biotechnology, Healthcare, Health Care
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, an
Key facts
- Headquarters
- HAYWARD, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (TLPH)
- Website
- acelrx.com
- Company page
Recent activity at ACELRX PHARMACEUTICALS
- : SEC 8-K (5.01): On March 11, 2026, Talphera, Inc. received a notice from the Listing Qualifications Staff of the Nasdaq Stock Market indicating that the company is not in compliance with the minimum bid price requirement of $1.00 per share as specified in Nasdaq Listing Rule 5550(a)(2). The notice states that the deficiency exists due to the stock’s failure to meet the minimum bid price for 30 consecutive business days. However, the notification does not affect the current listing of the company's common stock on Nasdaq, which will remain while the company has 180 calendar days to regain compliance. This situation could have strategic implications for the company’s market position and investor confidence.
- : SEC 8-K (1.01): On October 21, 2025, Talphera, Inc. entered into an Optional Closing of a previously disclosed securities purchase agreement with several institutional investors and a member of management. This agreement involves the issuance and sale of 1,023,890 shares of common stock at a purchase price of $0.586 per share as part of a private placement structured in three tranches. The conditions of certain subsections were waived to facilitate this second and third closing of the transaction. The initial closing of the private placement had taken place on April 2, 2025, indicating ongoing capital raising efforts by Talphera to strengthen its financial position.
- : ACELRX PHARMACEUTICALS
- : ACELRX PHARMACEUTICALS
- : ACELRX PHARMACEUTICALS
- : ACELRX PHARMACEUTICALS
- : ACELRX PHARMACEUTICALS INC
ACELRX PHARMACEUTICALS funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Venture | $17.0M |
| Apr 2025 | Seed | $4.9M |
| Jul 2023 | Venture | $10.0M |
| Aug 2022 | Venture | $630K |
| Jan 2022 | Venture | $5.2M |
Leadership
- Mark Wan, Director
- Howard Rosen, Director
- Stephen Hoffman, Director
- Marina Bozilenko, Director
- Jill Broadfoot, Director
- Richard Afable, Director
- Adrian Adams, Director
- Pamela Palmer, Executive Officer, Director
- Vincent Angotti, Executive Officer, Director
- Vincent Angotti, Executive Officer, Director
- Richard Afable, Director
- Marina Bozilenko, Director
Verified email and direct lines for ACELRX PHARMACEUTICALS’s decision-makers are on Fundz. See plans
Employee benefit plans
ACELRX PHARMACEUTICALS files 4 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
ACELRX PHARMACEUTICALS in the news
- AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics - PR Newswire (Jan 10, 2022)
- AcelRx becomes Talphera, adopting new name to reflect pain pivot - Fierce Pharma (Jan 10, 2024)
- FDA warns AcelRx of misleading ads for its pain drug Dsuvia - STAT (Feb 16, 2021)
- AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals - PR Newswire (Mar 14, 2023)
- AcelRx Pharmaceuticals: ACRX Stock Price Quote & News - Robinhood (Jul 22, 2023)
- AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain - News-Medical (Oct 06, 2015)
- AcelRx Pharma (ACRX) to Rebrand as Talphera, Inc - StreetInsider (Jan 09, 2024)
- AcelRx Pharmaceuticals Inc. (ACRX) Peer Comparison – Compare with Others - Value Research (Sep 01, 2026)
Companies similar to ACELRX PHARMACEUTICALS
- AbbVie Inc. · Biotechnology, Healthcare, Health Care, Manufacturing, Pharmaceutical
- Ionetix Corp · Biotechnology, Healthcare, Health Care, Manufacturing, Pharmaceutical
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Pharmaceutical
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical
About ACELRX PHARMACEUTICALS: questions and answers
What does ACELRX PHARMACEUTICALS do?
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, an
Where is ACELRX PHARMACEUTICALS headquartered?
ACELRX PHARMACEUTICALS is headquartered in HAYWARD, California, United States.
Has ACELRX PHARMACEUTICALS raised funding?
Yes. Fundz has recorded 5 funding events for ACELRX PHARMACEUTICALS. The most recent, $17.0M, was in Sep 2025.
What is the latest news on ACELRX PHARMACEUTICALS?
On Mar 11, 2026, SEC 8-K (5.01): On March 11, 2026, Talphera, Inc. received a notice from the Listing Qualifications Staff of the Nasdaq Stock Market indicating that the company is not in compliance with the minimum bid price requirement of $1.00 per share as specified in Nasdaq Listing Rule 5550(a)(2). The notice s
Is ACELRX PHARMACEUTICALS a public company?
Yes. ACELRX PHARMACEUTICALS is publicly traded under the ticker TLPH.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy